Myriad Genetics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - MYGN
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. for potential securities fraud. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test starting January 2025.
November 11, 2024 | 10:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities fraud after UnitedHealth announced it will stop covering the GeneSight test.
The investigation into potential securities fraud and the loss of coverage for a key product by a major insurer could negatively impact Myriad Genetics' stock price. The news is highly relevant and important for investors as it directly affects the company's financial outlook and legal standing.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100